To boost the chances of recouping the cost of innovation bets, pharma companies must leverage a multi-pronged strategy that includes picking winning medicines, using technologies like AI and bringing the right external assets into the clinical fold.
Oncology has long been pharma’s biggest bucket for R&D, with investment historically leading to some of pharma’s most impactful breakthroughs. In the coming years, innovations such as radiopharmaceuticals, new immunotherapies, and next-generation cell and gene therapies offer cutting-edge solutions in cancer care.
included in this trendline
Offered Free by: PharmaVoice's studioID and Cencora
See All Resources from: PharmaVoice's studioID and Cencora
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.